2-氧代-2-吡咯烷-1-乙胺 | 24152-95-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氧代-2-吡咯烷-1-乙胺
• 中文别名: (2-氧代-2-吡咯烷-1-基乙基)胺
• 英文名称: 2-amino-1-(pyrrolidin-1-yl)ethan-1-one
• 英文别名: 2-amino-1-(pyrrolidin-1-yl)ethanone；2-amino-1-(1-pyrrolidinyl)ethanone；α-aminoacetylpyrrolidine；2-amino-1-pyrrolidinylethanone；1-glycyl-pyrrolidine；1-Glycyl-pyrrolidin；2-Oxo-2-pyrrolidin-1-ylethanamine；2-amino-1-pyrrolidin-1-ylethanone
• CAS: 24152-95-2
• 化学式: C₆H₁₂N₂O
• mdl: MFCD08060127
• 分子量: 128.174
• InChiKey: SJNAQBNIUKINQH-UHFFFAOYSA-N

物化性质

• 沸点：
  262.1±23.0 °C(Predicted)
• 密度：
  1.117±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319
• 储存条件：
  存储条件：2-8°C，避光，惰性气体

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Oxo-2-pyrrolidin-1-ylethanamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Oxo-2-pyrrolidin-1-ylethanamine
CAS number: 24152-95-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H12N2O
Molecular weight: 128.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氧代-2-吡咯烷-1-乙胺 在 Pd-BaSO₄ 氢气 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 5.0h， 生成 (8S,11R,12S)-12-N-hydroxy-3-methyl-11-(2-methylpropyl)-2,10-dioxo-8-N-(2-oxo-2-pyrrolidin-1-ylethyl)-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide
  参考文献：
  名称：

  Design, Synthesis, and Structure−Activity Relationships of Macrocyclic Hydroxamic Acids That Inhibit Tumor Necrosis Factor α Release in Vitro and in Vivo

  摘要：

  To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the PI and P2 ' residues of acyclic anti-succinate-based hydroxamic acids. A variety of residues including amide, carbamate, alkyl, sulfonamido, Boc-amino, and amino were found to be suitable P1-P2 ' linkers. With an N-methylamide at P3 ', the 13-16-membered macrocycles prepared exhibited low micromolar activities in the inhibition of TNF-alpha release from LPS-stimulated human whole blood. Further elaboration in the P3 ' -P4 ' area using the cyclophane and cyclic carbamate templates led to the identification of a number of potent analogues with IC50 values of less than or equal to 0.2 muM in whole blood assay (WBA). Although the P3 ' area can accommodate a broad array of structurally diversified functional groups including polar residues, hydrophobic residues, and amino and carboxylic acid moieties, in both the cyclophane series and the cyclic carbamate series, a glycine residue at P3 ' was identified as a critical structural component to achieve both good in vitro potency and good oral activity. With a glycine residue at P3 ', an N-methylamide at P4 ' provided the best cyclophane analogue, SL422 (WBA IC50 = 0.22 muM, LPS-mouse ED50 = 15 mg/kg, po), whereas a morpholinylamide at P4 ' afforded the most potent and most orally active cyclic carbamate analogue, SP057 (WBA IC50 = 0.067 muM, LPS-mouse ED50 = 2.3 mg/kg, po). Further profiling for SL422 and SP057 showed that these macrocyclic compounds are potent TACE inhibitors, with K-i values of 12 and 4.2 nM in the porcine TACE assay, and are broad-spectrum MMP inhibitors. Pharmacokinetic studies in beagle dogs revealed that SL422 and SP057 are orally bioavailable, with oral bioavailabilities of 11% and 23%, respectively.

  DOI：

  10.1021/jm010127e
• 作为产物：
  描述：

  tert-butyl (2-oxo-2-(pyrrolidin-1-yl)ethyl)carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以72%的产率得到2-氧代-2-吡咯烷-1-乙胺
  参考文献：
  名称：

  （R）-PFI-2类似物作为组蛋白赖氨酸甲基转移酶SETD7抑制剂的构效关系研究

  摘要：

  SETD7是一种参与人类基因调控的组蛋白H3K4赖氨酸甲基转移酶。SETD7的异常表达与多种疾病有关，包括癌症。因此，SETD7被认为是开发新的表观遗传药物的良好靶标。迄今为止，鲜有报道报道靶向SETD7的选择性小分子抑制剂很少，最有效的是（R）-PFI-2。在此，我们报告了对（R）-PFI-2及其类似物的结构-活性关系研究。合成了（R）-PFI-2的29个结构类似物的文库，并评估了其对重组表达的人SETD7的抑制作用。发现关键的相互作用是盐桥和（R）-PFI-2的NH 2 +之间形成氢键 组和SETD7的Asp256和His252残基。

  DOI：

  10.1002/cmdc.201800242

文献信息

• [EN] HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS<br/>[FR] THIÉNOPYRIMIDINES CONTENANT UN GROUPE HÉTÉROCYCLOALKYLE POUR DES COMPOSITIONS PHARMACEUTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011104337A1

  公开（公告）日：2011-09-01

  The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

  本发明涉及包含噻吩并嘧啶化合物的新颖药物组合物。此外，本发明涉及利用本发明的噻吩并嘧啶化合物生产药物组合物，用于预防和/或治疗可通过抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）及其变体的激酶活性而影响的疾病。
• [EN] PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS<br/>[FR] PYRAZOLESULFONAMIDES EN TANT QU'AGENTS ANTITUMORAUX
  申请人：PELOTON THERAPEUTICS INC

  公开号：WO2020210139A1

  公开（公告）日：2020-10-15

  Compounds of formula I, that induce RBM39 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity are described herein.

  公式I的化合物，能诱导RBM39蛋白降解，包含这些化合物的药物组合物，以及使用这些化合物治疗与RBM39蛋白活性相关疾病的方法，在本发明中有所描述。
• [EN] IRAK INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'IRAK ET LEURS UTILISATION
  申请人：NIMBUS IRIS INC

  公开号：WO2012097013A1

  公开（公告）日：2012-07-19

  The present invention relates to compounds and methods useful for inhibiting one or more interleukin-l receptor-associated kinases ("IRAK"). In some embodiments, a provided compound inhibits IRAK-1 and IRAK-4. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及化合物和方法，用于抑制一个或多个白细胞介素-1受体相关激酶（"IRAK"）。在某些实施例中，所提供的化合物抑制IRAK-1和IRAK-4。该发明还提供了包括本发明化合物的药学上可接受的组合物，以及使用所述组合物治疗各种疾病的方法。
• HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
  申请人：LEHMANN-LINTZ Thorsten

  公开号：US20110212102A1

  公开（公告）日：2011-09-01

  The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

  本发明涉及包含噻吡啶并嘧啶化合物的新颖药物组合物。此外，本发明涉及利用本发明的噻吡啶并嘧啶化合物生产药物组合物，用于预防和/或治疗可通过抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）及其变体的激酶活性而影响的疾病。
• Chiral Aldehyde Catalysis for the Catalytic Asymmetric Activation of Glycine Esters
  作者：Wei Wen、Lei Chen、Ming-Jing Luo、Yan Zhang、Ying-Chun Chen、Qin Ouyang、Qi-Xiang Guo

  DOI：10.1021/jacs.8b06676

  日期：2018.8.1

  Chiral aldehyde catalysis is uniquely suitable for the direct asymmetric α-functionalization of N-unprotected amino acids, because aldehydes can reversibly form imines. However, there have been few successful reports of these transformations. In fact, only chiral aldehyde catalyzed aldol reactions of amino acids and alkylation of 2-amino malonates have been reported with good chiral induction. Here

  手性醛催化特别适用于 N-未保护氨基酸的直接不对称 α-官能化，因为醛可以可逆地形成亚胺。然而，关于这些转变的成功报道很少。事实上，只有手性醛催化氨基酸的羟醛反应和 2-氨基丙二酸酯的烷基化具有良好的手性诱导作用。在这里，我们报告了一种基于烯醇中间体表面控制的新型手性醛催化剂。由此产生的手性醛是第一种有效的非吡哆醛依赖性催化剂，可以促进 N-未保护甘氨酸酯的直接不对称 α-官能化。通过密度泛函理论计算研究了可能的过渡态和质子转移过程。